Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2015 16:02 ET | Source: VBL Therapeutics

VBL Therapeutics Presents Positive Data on VB-111 in Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer at the ITC 2015 Conference

TEL AVIV, Israel, Oct. 21, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced positive results from its multi-cohort Phase 2 trial of VB-111 in advanced radioiodine-refractory...
September 28, 2015 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival

TEL AVIV, Israel, Sept. 28, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced full Phase 2 data on VB-111 in combination with Bevacizumab (Avastin™) in rGBM. Data were...
September 17, 2015 16:01 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

TEL AVIV, Israel, Sept. 17, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
August 20, 2015 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Trial of VB-111 in Recurrent Glioblastoma

TEL AVIV, Israel, Aug. 20, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that the first patient has been dosed in the Company's GLOBE™ Study, a pivotal Phase 3 trial of...
August 13, 2015 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2015 Financial Results and Provides Business Update

-- Reported Strengthened, Statistically Significant Interim Data From VB-111 Phase 2 Study in rGBM -- -- Reported Clinically Meaningful Interim Data From VB-111 Phase 1/2a Study in...
August 06, 2015 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015

TEL AVIV, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
July 14, 2015 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Data on Proprietary Gene Therapy Vascular Targeting System(TM) and Lead Product VB-111 - at Drug Discovery and Therapy World Congress 2015

TEL AVIV, Israel, July 14, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
June 01, 2015 07:30 ET | Source: VBL Therapeutics

VBL Therapeutics Reports Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)

TEL AVIV, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
May 30, 2015 14:15 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Phase 1/2a Data From VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

TEL AVIV, Israel, May 30, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
May 26, 2015 08:30 ET | Source: VBL Therapeutics

VBL Therapeutics to Webcast Analyst and Investor Event at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2015

TEL AVIV, Israel, May 26, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right